Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-01-15

Clinical Trial Update: Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting efficacy and tolerability of lanreotide (Autogel 120 mg) in acromegaly.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lanreotide (lanreotide)

Snippet

Sponsor: Ipsen | Conditions: Acromegaly | Phase 3 | Status: COMPLETED